Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Webcasts

Transforming Oral Drug Products for Late-Phase and Commercial Excellence

November 12, 2024

Webinar Date/Time: Tue, Dec 3, 2024 11:00 AM EST

MD Anderson Launches Cell Therapy Institute

November 11, 2024

The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.

Bespak and Orbia Fluor & Energy Materials Collaborate on Climate-Friendly Inhalers

November 08, 2024

The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.

Oblenio Bio Created by Aditum Bio and Leads Biolabs to Develop Therapeutic Antibody for Treating Autoimmune Disorders

November 08, 2024

In the collaboration, the new company, Oblenio Bio, has been granted an exclusive option to license LBL-051, a tri-specific T-cell engager antibody, from Leads Biolabs.

Aptamer Extends Agreement for Drug Delivery Vehicles

November 07, 2024

A genetic medicines customer has selected the company’s binders for commercial development of the customer’s product.

Accelerating Discovery and Development with Advances in High-Throughput Screening

November 07, 2024

Automation, miniaturization, and new software algorithms are improving throughput and accuracy.

Synaffix, a Lonza Company, Collaborates with BigHat Biosciences on ADCs Designed Using Machine Learning

November 07, 2024

Synaffix, a Lonza company, has licensed its ADC technology to BigHat Biosciences to be combined with the latter's ML design platform to develop new ADCs

FDA Rare Disease Innovation Moves Forward

November 01, 2024

CDER Director Patrizia Cavazzoni and CBER Director Peter Marks provided an update on the rare disease innovation hub in a new FDA Voices blog post.

Lilly and ViaNautis Bio Partner on Development of Novel Therapeutics Delivering Genetic Cargo

October 31, 2024

The partnership will use ViaNautis’ proprietary polyNaut technology platform to develop genetic medicines that can precisely target tissue types.

Webcasts

Focusing on Solid Dosage Trends and Demand

October 30, 2024

Webinar Date/Time: Fri, Nov 22, 2024 11:00 AM EST